Denied by Hongkong SEC, the acquisition deal of Lijun International Pharmaceutical from Kelun Group officially has being dropped today.

 China’s Kelun Group, Beijing Double-crane Pharmaceutical Co. and Lijun International Pharmaceutical account for over half of domestic LargeVolume Parenteral market. As the authority imposed GMP (Good Manufacturing Practice) and GSP( Good supply practice) policy, the entire medical device system is to embrace reshuffle. Also, the major medical device manufacturers face slowing growth speed. It is very obvious that the domestic LargeVolume Parenteral market is very saturated now.